- Home
- VNOM vs NUVL Comparison
VNOM vs NUVL Comparison
Compare VNOM & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNOM
- NUVL
- Stock Information
- Founded
- VNOM 2013
- NUVL 2017
- Country
- VNOM United States
- NUVL United States
- Employees
- VNOM N/A
- NUVL N/A
- Industry
- VNOM Oil & Gas Production
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- VNOM Energy
- NUVL Health Care
- Exchange
- VNOM Nasdaq
- NUVL Nasdaq
- Market Cap
- VNOM 4.9B
- NUVL 5.6B
- IPO Year
- VNOM 2014
- NUVL 2021
- Fundamental
- Price
- VNOM $40.57
- NUVL $69.85
- Analyst Decision
- VNOM Strong Buy
- NUVL Strong Buy
- Analyst Count
- VNOM 13
- NUVL 8
- Target Price
- VNOM $56.62
- NUVL $115.50
- AVG Volume (30 Days)
- VNOM 1.0M
- NUVL 625.4K
- Earning Date
- VNOM 05-05-2025
- NUVL 05-08-2025
- Dividend Yield
- VNOM 6.09%
- NUVL N/A
- EPS Growth
- VNOM 42.93
- NUVL N/A
- EPS
- VNOM 3.82
- NUVL N/A
- Revenue
- VNOM $857,200,000.00
- NUVL N/A
- Revenue This Year
- VNOM $51.98
- NUVL N/A
- Revenue Next Year
- VNOM $19.97
- NUVL N/A
- P/E Ratio
- VNOM $10.62
- NUVL N/A
- Revenue Growth
- VNOM 3.86
- NUVL N/A
- 52 Week Low
- VNOM $34.71
- NUVL $55.54
- 52 Week High
- VNOM $56.76
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- VNOM 48.19
- NUVL 46.22
- Support Level
- VNOM $38.88
- NUVL $63.56
- Resistance Level
- VNOM $42.30
- NUVL $78.97
- Average True Range (ATR)
- VNOM 1.32
- NUVL 3.46
- MACD
- VNOM 0.12
- NUVL -0.38
- Stochastic Oscillator
- VNOM 49.49
- NUVL 40.84
About VNOM Viper Energy Inc.
Viper Energy Inc is focused on owning and acquiring mineral and royalty interests in oil and natural gas properties primarily in the Permian Basin. The Permian Basin is known to have a number of zones of oil and natural gas-bearing rock throughout.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.